2024
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosis
2016
Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined?
Leapman M, Cooperberg M. Clinical Risk Prediction Tools for Prostate Cancer: TNM to CAPRA—Should Risk Be Redefined? 2016, 33-52. DOI: 10.1007/978-3-319-21485-6_3.Peer-Reviewed Original ResearchPrimary androgen deprivation therapyClinical risk prediction toolsUCSF-CAPRA scoreAndrogen deprivation therapyRisk stratification toolPretreatment clinical variablesRisk prediction toolsProstate cancer biologyProstate Cancer Risk PredictionCancer risk predictionAdvanced diseaseDeprivation therapyReliable risk estimationClinical characteristicsStratification toolClinical stageClinical variablesGleason scoreOutcomes warrantsRisk groupingPostsurgical settingProstate cancerInternational cohortClinical prognosticationNovel biomarkers